
Covid-19 vaccine for 5- to 11-year-olds is safe and shows 'robust' antibody response, Pfizer says
CNN
A Phase 2/3 trial of Pfizer/BioNTech's two-dose Covid-19 vaccine for children ages 5 to 11 showed it is safe and generated a "robust" antibody response.
These are the first such results released for this age group for a US Covid-19 vaccine, and the data has not yet been peer-reviewed or published. Pfizer said it plans to submit to the US Food and Drug Administration for emergency use authorization soon.
The trial included 2,268 participants ages 5 to 11 and used a two-dose regimen of the vaccine administered 21 days apart. This trials used a 10-microgram dose -- smaller than the 30-microgram dose that has been used for those 12 and older.

The two men killed as they floated holding onto their capsized boat in a secondary strike against a suspected drug vessel in early September did not appear to have radio or other communications devices, the top military official overseeing the strike told lawmakers on Thursday, according to two sources with direct knowledge of his congressional briefings.












